Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Beyond Air Inc XAIR

Healthcare Medical Devices
Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received United States Food and Drug Administration (FDA) approval for its first system, LungFit PH, for... see more

Recent & Breaking News (NDAQ:XAIR)

AIT Strengthens Executive Leadership Team with Appointment of Chief Commercial Officer

GlobeNewswire January 2, 2019

AIT Nearing Definitive Agreement to License Commercial Rights of Its Novel Ventilator Compatible Nitric Oxide Generator and Delivery System for Use in the Hospital Setting in the United States and a Second Country

GlobeNewswire December 28, 2018

AIT Therapeutics Reports Financial Results for Fiscal Second Quarter 2019

GlobeNewswire November 14, 2018

AIT Therapeutics to Present at the 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum

GlobeNewswire November 5, 2018

AIT Therapeutics Schedules Fiscal Second Quarter 2019 Financial Results Conference Call and Webcast

GlobeNewswire October 31, 2018

AIT Therapeutics Appoints Douglas J. Beck as Chief Financial Officer

GlobeNewswire October 26, 2018

AIT Therapeutics Presented Its High-Dose Nitric Oxide In Vitro Data at the North American Cystic Fibrosis Conference

GlobeNewswire October 18, 2018

OTC Markets Group Announces Quarterly Index Performance and Rebalancing

PR Newswire October 17, 2018

AIT Therapeutics to Present High-Dose Nitric Oxide In Vitro Data at the North American Cystic Fibrosis Conference

GlobeNewswire October 16, 2018

AIT Therapeutics to Present at the Ladenburg 4th Annual Healthcare Conference

GlobeNewswire September 26, 2018

AIT Therapeutics Presented Nitric Oxide Data at the European Respiratory Society International Congress 2018

GlobeNewswire September 19, 2018

AIT Therapeutics Announces $526,500 Sale of Common Stock To Institutional Investor, Lincoln Park Capital Fund

GlobeNewswire September 5, 2018

AIT Therapeutics to Present Nitric Oxide Data at Two Upcoming Scientific Conferences

GlobeNewswire September 4, 2018

AIT Therapeutics Reports Financial Results for First Fiscal Quarter 2019

GlobeNewswire August 14, 2018

AIT Therapeutics Announces $20 Million Common Stock Purchase Agreement with Institutional Investor, Lincoln Park Capital Fund

GlobeNewswire August 13, 2018

AIT Therapeutics Schedules Fiscal First Quarter 2019 Financial Results Conference Call and Webcast

GlobeNewswire August 1, 2018

AIT Therapeutics Announces Start of Manufacturing of Ventilator Compatible NO Generator and Delivery System

GlobeNewswire July 30, 2018

AIT Therapeutics Announces Human and In-Vitro Nitric Oxide (NO) Data Presented at the 3rd Annual World Bronchiectasis Conference

GlobeNewswire July 16, 2018

AIT Therapeutics Announces Human and In-Vitro Nitric Oxide Data to be Presented at the 3rd Annual World Bronchiectasis Conference

GlobeNewswire June 27, 2018

AIT Therapeutics Reports Positive Top Line Results from its Nitric Oxide in Bronchiolitis (NO-BRO) Pilot Study in Infants

GlobeNewswire June 13, 2018